Diagnostic tests and criteria are not certified in this packet. A research record in the packet describes a planned study of early biomarkers of the impacts of perinatal asphyxia, which indicates that biomarker work is ongoing but does not describe an established diagnostic method.

Treatment coverage is not certified in this packet, and no FDA-approved treatments are recorded. FDA orphan drug designations exist for several investigational agents with indications that include neonatal hypoxic-ischemic encephalopathy or perinatal asphyxia; an orphan designation does not indicate approval, development status, or availability.

Prognosis is not certified in this packet.

The packet's ClinicalTrials.gov records for this condition include a not-yet-recruiting phase 2 study of intranasal stem cells for perinatal brain injury (UMC Utrecht) and a not-yet-recruiting multimodal biomarker study of the impacts of perinatal asphyxia (Amiens University Hospital). Many other records matched through the term perinatal concern maternal mental health and are not specific to this condition. Active clinical trials for this condition are listed on ClinicalTrials.gov.